Dr. Sonia Hassan comments in New York Times article examining progesterone's role in reducing preterm births
The hormone progesterone, administered by injection or vaginally to pregnant women, has been helpful in reducing the chances that a woman who has had one preterm birth will have another. Two previous trials have also found progesterone useful in preventing preterm births among women with a short cervix, another known risk group. But those studies, using the vaginal form of the drug, looked only at women who had a cervical length of less than 20 millimeters - only 2 percent of the population.
Scientists have hoped the hormone would benefit even more women, making a significant dent in the number of preterm births each year. Now a new randomized double-blinded trial, published online in The American Journal of Obstetrics & Gynecology, reports that progesterone in its injected form does not work for a much larger risk group: the 10 percent of women with a cervix shorter than 30 millimeters. These women have about the same risk of having a preterm birth - around 25 percent - as those who have already had one. Some researchers, like Dr. Sonia S. Hassan, associate dean for maternal, perinatal and child health at Wayne State University, supports cervical length screening for all pregnant women. "If it's found to be short," she said, "they should receive vaginal progesterone. The injectable form is commonly used for women with a prior preterm birth. I would advise women to speak with their physicians to see if they are candidates for that."